Pharmaceutical Indications

 

42 Results were found on Technologies

Leading Researchers:
10-2011-259

Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal Model

Cerebrovascular dysfunction is a fundamental part of the pathology of several neurodegenerative diseases and rated as one of the most prominent cause for dementia. Cerebral amyloid angiopathy (CAA) results in intra-parenchymal and subarachnoid bleeding, which is caused by cerebrovascular amyloid deposits and multiple infarcts, and can lead to hemorrhagic stroke and cognitive impairment (Greenberg et […] Read More >

Leading Researchers:
5-2012-401

Biomarkers for Risk Assessment in Colorectal Cancer Patients

Mortalin (also known as GRP75 and mitochondrial stress protein 70) is a ubiquitously expressed mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). It protects cells from senescence and apoptosis and is overexpressed in most cancer cells. We discovered that cell resistance to complement-dependent cytotoxicity depends on mortalin and that mortalin is released […] Read More >

Leading Researchers:
10-2013-551

Novel Integrase Based Cancer Treatment Technology

We have developed a new gene therapy technology for specific cancer cells killing and validated both efficacy and safety superiority of the proposed system over the conventional one in lung cancer mice model. The proposed system offers advantages over already known counterparts and may therefore be developed into a safer and efficient human cancer treatment […] Read More >

Leading Researchers:
10-2007-103

Improved Calcitonin-based Therapeutics

TechnologyThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. The NeedThe therapeutic use of human calcitonin is severely limited by its tendency to associate […] Read More >

Leading Researchers:
2-2011-142

IAPP Oligomers as a Target for Type 2 Diabetes Novel Immunotherapy

TechnologyStabilized human IAPP (hIAPP) oligomers were used for the development of active immunization of type 2 diabetes. This promising novel approach for the treatment of type 2 diabetes is doable due to the establishment of a new protocol for the formation of stable islet amyloid polypeptide (IAPP) amyloidal soluble oligomers in vitro, leading to isolation […] Read More >

Leading Researchers:
5-2011-178

Quantitative confluency measurement of culture growth

The invention is an image processing method of light microscopy images for the purpose of quantifying density of  cells in cultures . A grayscale image of a cell culture is digitally captured using a light microscope and a CCD camera.  Our method evaluates the culture’s confluency using an image processing algorithm on the image which […] Read More >

Leading Researchers:
5-2011-249

METHODS AND KITS FOR DETERMINING PREDISPOSITION TO DEVELOP KIDNEY DISEASES

Many rare kidney disorders exhibit a monogenic, Mendelian pattern of inheritance. Population-based genetic studies have identified many genetic variants associated with an increased risk of developing common kidney diseases. Strongly associated variants have potential clinical uses as predictive markers and may advance our understanding of disease pathogenesis. These principles are elegantly illustrated by a region […] Read More >

10-2013-549

Novel specific disease-modifying PERK activator for Huntington’s disease

There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. Gene therapy-based clinical trials have failed so far, highlighting the need for other approaches. These include the recent interruption of antisense oligonucleotide clinical trials for HD. Background• Endoplasmic reticulum (ER) […] Read More >

Leading Researchers:
10-2018-1153

An Oncolytic Virus That Exploits Immune Defects of Cancer Cells

An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy.  Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEEDOn Nov. 2015 the FDA approved the first oncolytic virus based treatment. Oncolytic […] Read More >

Leading Researchers:
2-2016-991

A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues

UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >

Prof. Ben-Eliyahu Shamgar

I am a neuroscientist specializing in Psycho-Neuro-Immunology (PNI). The field of PNI studies interactions between the central nervous system (CNS), the endocrine system, and the immune system. Bidirectional influences between these systems affect susceptibility to diseases, cognition, mood, and behavior, as well as neurodevelopmental processes. Within the realm of PNI, my main research interests are […] Read More >

Prof. Benayahu Dafna

Nanomedicine is medical treatment at the level of single molecules or molecular assemblies that provide structure, control, signaling, homeostasis, and motility in cells, i.e., at the “nano” scale of about 100 mm or less. There have been many scientific and technological advances in both physical and biological sciences over the past several years that make nano medicine […] Read More >

Prof. BENAYAHU Yehuda

Read More >

Prof. Benhar Itai

Prof. Benhar is an expert and opinion leader in the field of antibody engineering. Over the 25 years of being active in that field, he prepared several phage display libraries from which antibodies against numerous targets were isolated. Prof. Benhar publishes over 100research papers, wrote 10 book chapters and submitted 19 patent applications. Research in Prof. […] Read More >

Prof. BINDERMAN Itzhak

Read More >

Dr. Burstein David

Dr. Burstein is a faculty member in The Shmunis School of Biomedicine and Cancer Research in the Life Science Faculty at Tel Aviv University. His research focuses on CRISPR-Cas systems, secretion systems of pathogens, and the discovery of novel antibiotic resistance genes to better understand fundamental interaction mechanisms within microbial communities and to promote their […] Read More >

Prof. Canaani Dan

Preface Previously, my laboratory has concentrated on isolation of human DNA repair genes, and in particular checkpoint genes for DNA damage. For this purpose we introduced the approach of isolating human DNA repair genes by expression cloning of cDNA libraries (Teitz et al., 1987; 1988; 1989). This approach has initially resulted in our identification of […] Read More >

Prof. Dvir Tal

Microfluidics-based tissue engineering. Recreating stem cell niches, microfluidics bioreactors for tissue engineering. Nanotechnological strategies for engineering thick cardiac tissue. Engineering a 3D neuronal network for spinal cord and brain regeneration. Fabrication of Nanoelectronics/engineered tissue hybrids. Developing smart delivery systems that recruit stem cells to defected organs. Email: tdvir@tauex.tau.ac.il Phone: 03-6406514 Another phone: 03-6408604 Website: https://dvirlab.wixsite.com/dv… Office: […] Read More >

Prof. Efrat Shimon

Our research focuses on the development of a cell replacement therapy for diabetes, in which the insulin-producing pancreatic beta cells are destroyed or malfunction. Our approaches for generation of an abundant source of cells for transplantation include expansion and differentiation in tissue culture of beta cells from human organ donors, as well as differentiation of […] Read More >

Prof. EHRLICH Marcelo

I am interested on the dynamic aspects of the cell’s trafficking machinery, with a special focus on endocytic dynamics. More specifically, our study centers on the mechanisms by which the cell modulates vesicular traffic by altering: The rate of formation of vesicular carriers, such as clathrin coated vesicles. The spatio-temporal distribution of the process of […] Read More >

Leading Researchers:
12-2013-717

MULTI SENSOR – Multi Modal Recording System for Behavioral Tracking

It is clear today that brain activity of a restrained (or sedated) animal is completely different from that of a freely behaving animal.That is why neuroscientists are seeking to find ways to study animals freely behaving on their natural grounds.TAU’s interdisciplinary research has led to the development of the MULTI SENSOR – Multi Modal Recording […] Read More >

Leading Researchers:
12-2013-676

analysis of mineralized tissues using microCT

The general purpose of my research is to describe the genetic and endocrine regulation of bone metabolism. To this end, we developed expertise in most aspects of bone research, from in vivo models, imaging of bone microarchitecture, in vitro cell cultures and molecular biology. Main Research Topics Regulation of bone metabolism by sex steroids Role […] Read More >

Leading Researchers:
12-2013-622

Laboratory of endoplasmic reticulum (ER) quality control and protein misfolding diseases

Lab DescriptionMain areas of interest are in the mechanisms of protein folding and trafficking in the early secretory pathway of mammalian cells and the development of ER stress upon their malfunction, particularly in neurodegenerative diseases.  Specific research topics are:• Protein misfolding diseases, including neurodegenerative diseases.• ER stress.• Mechanisms of endoplasmic reticulum (ER) protein folding and quality control.• Sugar chain […] Read More >

Leading Researchers:
12-2013-434

The Cohen Rosenthal Diabetic Hypertensive Rat (CRDH) model

The construction of the Cohen Rosenthal Diabetic Hypertensive Rat (CRDH) model was initiated nearly a decade ago by cross-breeding between the Cohen Diabetic rat (CDR) and the SHR. The CDR is a rodent model that expresses the following phenotypes: when fed regular diet, it is non-diabetic; when fed a diabetogenic diet, it invariably develops diabetes […] Read More >

Leading Researchers:
12-2013-415

Laboratory of Immunological and Inflammatory Modules in Malignancy

Research focusProf. Ben-Baruch is an immunologist who investigates the roles of immune and inflammatory elements in physiological and pathological conditions, with major emphasis on malignancy. The studies in her laboratory determine the complex regulatory networks established between chemokines and cytokines of the tumor microenvironment, intrinsic oncogenic modifications in tumor cells, and stroma cells. The research […] Read More >

Leading Researchers:
12-2011-229

Advanced Materials

The Biomaterials and Corrosion LaboratoryIby and Aladar Fleischman Faculty of Engineering, Tel-Aviv University, Israel   In line with the demands of modern society, the multidisciplinary Biomaterials and Corrosion Laboratory is conducting strategic R&D on advanced materials ranging from biomaterials and nanomaterials, to materials for space applications, alloy deposition and archaeology. The Lab also provides materials […] Read More >

Leading Researchers:
12-2016-1018

Lab of Signal transduction, Neurodegeneration and Autophagy

Research focus ErbB receptors interactions and functions Regulation of Autophagy Neurodegeneration  Projects include:The crosstalk between ErbB receprots and nucleolin in cancer developmentBeclin 1 mediated autophagyAutophagy in neurodegenerative diseasesAutophagy in cancer Potential servicesLaboratory services:To monitor autophagySignal transduction assaysAnti-cancer drugs examinationCell proliferation, death and migration examination   Potential industries1.    Pharma2.    BiotechContact InformationProf. Pinkas-Kramarski RonitDept. of Neurobiology, Life […] Read More >

Leading Researchers:
12-2016-982

Lab of Molecular Neurodegeneration

The goal of the lab is to elucidate molecular mechanisms of motor neuron survival and proper function using ALS disease as a model. In our current efforts we are using cutting edge in vitro and in vivo technologies studying molecular mechanisms of: 1.    Molecular communication of trophic factors (such as BDNF or GDNF) between […] Read More >

Leading Researchers:
12-2016-972

Lab of Cancer Angiogenesis and Nanomedicine

Selective therapy remains a key issue for successful treatment in cancer therapy. Prolonged administration of effective concentrations of chemotherapeutic or anti-angiogenic agents is usually not possible because of dose-limiting systemic toxicities involving non-malignant tissues. Therefore, a constant effort has been the development of new drug delivery systems that mediate drug release selectively at the tumor […] Read More >

Leading Researchers:
12-2011-225

Synthesis of Organic Compounds

Custom synthesis of organic compounds   Industrial Research Services: We offer services for custom synthesis of small organic compounds. Our laboratories in Tel Aviv University have all the basic state-of-the-art instrumentation for synthetic capabilities. The School of Chemistry also has an Analytical Research and Instrumentation Unit, which provides services for organic analyses. The Department of […] Read More >

Sorry, no results were found.

Sign up for
our events

    Close
    Life Science
    Magazine

      Close
      Hi-Tech
      Magazine

        Close